Retained Earnings (Accumulated Deficit) of Kuvatris Therapeutics, Inc. from 31 Dec 2021 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Kuvatris Therapeutics, Inc. quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Dec 2021 to 30 Sep 2024.
  • Kuvatris Therapeutics, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending 30 Sep 2024 was $59,597,347, a 29% decline year-over-year.
Source SEC data
View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

Kuvatris Therapeutics, Inc. Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $59,597,347 -$13,488,079 -29% 30 Sep 2024 10-Q 14 Jan 2026 2024 Q3
Q2 2024 $58,720,705 -$17,660,655 -43% 30 Jun 2024 10-Q 20 Sep 2024 2024 Q2
Q1 2024 $55,722,926 -$18,149,163 -48% 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 $52,029,741 -$18,289,725 -54% 31 Dec 2023 10-Q 14 Jan 2026 2024 Q3
Q3 2023 $46,109,268 -$17,589,900 -62% 30 Sep 2023 10-Q 16 Nov 2023 2023 Q3
Q2 2023 $41,060,050 -$24,004,295 -141% 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $37,573,763 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $33,740,016 -$14,801,767 -78% 31 Dec 2022 10-K 11 Mar 2024 2023 FY
Q3 2022 $28,519,368 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $17,055,755 30 Jun 2022 10-Q 30 Sep 2022 2022 Q2
Q4 2021 $18,938,249 31 Dec 2021 10-K 30 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.